Journal
CANCER LETTERS
Volume 502, Issue -, Pages 97-107Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.12.042
Keywords
ROC; LncRNA; Recurrence; Metastasis; Drug resistance; Cancer biomarker
Categories
Funding
- Overseas Research Cooperation Project (Tsinghua Shenzhen International Graduate School), China [HW2020008]
- Shenzhen Development and Reform Commission Subject Construction Project, China [[2017]1434]
- TBSI Faculty Start-up Funds, China
- Shenzhen Bay Laboratory, China
Ask authors/readers for more resources
Nearly 70% of ovarian cancer patients experience recurrence within the first 2 years after initial treatment. Emerging evidence suggests that long non-coding RNAs play a pivotal role in OC progression, therapy resistance and recurrent OC. Studies have reported differential expression patterns of lncRNAs in OC, which are related to increased invasion, metastasis and drug resistance.
Nearly 70% of ovarian cancer (OC) patients experience recurrence within the first 2 years after initial treatment. Emerging evidence indicates that long non-coding RNAs (lncRNAs) play a pivotal role in the pathogenesis of OC progression, resistance to therapy and recurrent OC (ROC). Transcriptome profiling studies have reported differential expression patterns of lncRNAs in OC which are related to increased cell invasion, metastasis and drug resistance. In this review, we highlighted the roles of lncRNAs in OC progression and outlined the potential molecular mechanisms by which lncRNAs impact on ROC. Recent advances using lncRNAs as potential biomarkers for screening, detection, prediction, response to therapy and as therapeutic targets are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
